The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Establishment of a Registry and a Biorepository of Patients With Suspected Amniotic Fluid Embolism (AFE) (AFE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05791786
Recruitment Status : Recruiting
First Posted : March 30, 2023
Last Update Posted : April 3, 2023
Sponsor:
Collaborator:
Amniotic Fluid Embolism (AFE) Foundation
Information provided by (Responsible Party):
Irene Stafford, The University of Texas Health Science Center, Houston

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
To establish a clinical registry of suspected cases of AFE. The existing registry will be migrated to a new platform,

Condition or disease Intervention/treatment
Amniotic Fluid Embolism Other: Patient

Detailed Description:

The registry and the biorepository have prospective and retrospective components.

The prospective component of the registry and the biorepository focuses on the collection of demographic, clinical, and biological material of patients prospectively identified as having the AFE syndrome, including the collection of future samples from survivors and related individuals. Typically, healthcare providers, family members of an affected patient, or patients themselves contact the AFE Foundation. The AFE Foundation provides information about the natural history of the syndrome and its outcomes and invites patients to participate in the registry and biorepository. The AFE Foundation obtains informed consent from patients or next of kin for enrollment in this observational study. There is no randomization or placebo group for this registry as it is exclusively an observational study. If maternal specimens are available pre- and post-event during the hospital admission for delivery, these samples will also be collected from each patient. The only group assignment will be the subjects with a diagnosis of AFE and the subjects' family members including the partner(s) and child (children).

The retrospective component of the registry consists of obtaining clinical information and biological material from patients who have been previously affected by the AFE syndrome. This objective includes obtaining medical records, patient-provided information, pathology reports, autopsy reports, and tissue blocks. Biological samples can also be obtained from survivors and relatives to determine whether there are biomarkers in previously affected patients or whether biomarkers can be elicited from the stimulation of peripheral blood cells. In addition to collecting data and specimens from the patients that are consented and enrolled through the registry, a query of all maternal deaths within 24 hours of birth between 1/2012 to 1/2023 will be performed at the Hermann Hospital system to identify if any of these deaths occurred secondary to AFE. The investigators intend to perform a detailed chart review and collect otherwise discarded tissue if available from the respective hospital to perform special immunohistochemistry staining among women who underwent autopsy.

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 400 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 2 Weeks
Official Title: The Establishment of a Registry and a Biorepository of Patients With Suspected Amniotic Fluid Embolism (AFE)
Actual Study Start Date : July 5, 2022
Estimated Primary Completion Date : October 1, 2031
Estimated Study Completion Date : December 31, 2031
Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
AFE

participants of the AFE registry and biorepository include affected individuals diagnosed with AFE

All subjects or their next of kin must be able to provide a signed and dated informed consent form.

In the case of lethal AFE, the surviving family member or next of kin must be able to provide a signed and dated informed consent form with an accompanying death certificate and proof of legal kinship

 Other: Patient
affected individuals diagnosed with AFE


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. To establish a clinical registry of suspected cases of AFE [ Time Frame: 1 year ]
    The existing registry will be migrated to a new platform, thus to enhance and strengthen the content and the quality of the data obtained.

  2. The existing registry will be migrated to a new platform, thus to enhance and strengthen the content and the quality of the data obtained. [ Time Frame: 2 weeks ]
    biological materials would be sought from mothers, their children, and other related individuals

  3. To obtain clinical data and biological specimens from individuals previously enrolled in the registry [ Time Frame: 3 weeks ]
    This objective includes the review of autopsy material and pathology reports, as well as the collection of biological material of survivors and members of the family, to determine whether there is a susceptibility to the AFE syndrome


Biospecimen Retention:   Samples Without DNA
Maternal blood, umbilical cord blood, and neonatal samples:

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Pregnant and postpartum women, survivors, offspring, and relatives of patients with suspected AFE through enrollment or chart review.
Criteria

Inclusion Criteria for participants of the AFE registry and biorepository include affected individuals diagnosed with AFE (see below).

  • All subjects or their next of kin must be able to provide a signed and dated informed consent form.
  • In the case of lethal AFE, the surviving family member or next of kin must be able to provide a signed and dated informed consent form with an accompanying death certificate and proof of legal kinship.
  • Participants are expected to be willing to permit collection of data about their affected pregnancy, previous and future pregnancies, and their current and future health conditions.
  • Providing biological samples is not required for enrollment.
  • Any maternal death in the Hermann Hospital System suspected of having an AFE within 24 hours of childbirth between 1/2012 and 1/2023 will also be included for data analysis and biospecimen studies

  • Medical records will be abstracted into a comprehensive case report form and then reviewed by a team of three experts with consensus to determine case classification of three categories, according to criteria previously reported and based on data generated from the previously existing registry:

    (1) Classic AFE is defined by the following indicators:

  • Acute hypotension or cardiac arrest,
  • Acute hypoxia, defined as dyspnea, cyanosis, or respiratory arrest,
  • Coagulopathy, defined as laboratory evidence of intravascular consumption or fibrinolysis or severe clinical hemorrhage in the absence of other explanations,
  • Onset of the above during labor, cesarean section, or dilation and evacuation or within 30 minutes post-partum, and

  • Absence of any other significant confounding condition or potential explanation for the signs and symptoms observed.

    (2) Not AFE:

  • Anything that clinically appears to be a likely result of another pathophysiology, e.g., delayed treatment of postpartum hemorrhage from uterine atony.

    (3) Atypical AFE:

  • Subjective determination by the chart reviewer that lies between "classic" and "not," e.g., the patient presents some of the registry criteria and no other explanation.

    (4) Indeterminate: There is not sufficient information to classify in 1-3 above.

The classification of AFE is for research purposes only.

Exclusion Criteria:

  • The inability of an individual to provide a signed and dated informed consent form or those who do not wish to participate.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05791786


Contacts
Layout table for location contacts
Contact: Miranda Klassen 760-444-5505 miranda@afesupport.org
Contact: Irene Stafford, MD 713-500-6412 irene.stafford@uth.tmc.edu

Locations
Layout table for location information
United States, Texas
The University of Texas Health Science Center at Houston Recruiting
Houston, Texas, United States, 77030
Contact: Sunbola Ashimi, PhD    713-500-6410    sunbola.s.ashimi@uth.tmc.edu   
Sponsors and Collaborators
The University of Texas Health Science Center, Houston
Amniotic Fluid Embolism (AFE) Foundation
Investigators
Layout table for investigator information
Principal Investigator: Irene Stafford, MD UT Health Science Center Health Science Center
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Irene Stafford, Associate Professor, The University of Texas Health Science Center, Houston
ClinicalTrials.gov Identifier: NCT05791786    
Other Study ID Numbers: HSC-MS-21-1004
First Posted: March 30, 2023    Key Record Dates
Last Update Posted: April 3, 2023
Last Verified: March 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Embolism, Amniotic Fluid
Embolism
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
 Pregnancy Complications, Cardiovascular
Pregnancy Complications
Female Urogenital Diseases and Pregnancy Complications
Urogenital Diseases